• Utility Study indicates KidneyIntelX risk assessment can address treatment ambiguity in primary care.
  • Renalytix announces new data demonstrating that KidneyIntelX can be effective at monitoring SGLT2i therapeutic response and improvements in kidney health over time in adults with Type 2 diabetes.


  • Renalytix partners with Atrium Health, Wake Forest Baptist Health and Wake Forest School of Medicine to reduce impact of kidney disease in large populations.


  • Multi-Center Study finds KidneyIntelX 72% more effective than the current standard of care in identifying early-stage patients at higher risk for disease progression and failure.
  • Clinical Utility Study demonstrates that primary care physicians are highly likely to order KidneyIntelX to inform care decisions.
  • Renalytix and Joslin Diabetes Center enter exclusive option agreement for patent filings on select additional novel biomarkers in kidney disease for development and deployment in the KidneyIntelX platform.
  • KidneyIntelX demonstrates performance and informs treatment decisions in multinational CANagliflozin CardioVAScular Assessment Study (CANVAS).
  • U.S. General Services Administration grants 10-year governmentwide contract for KidneyIntelX testing.